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Yazdi et al describe B-raf mutations in nevi with a particular his-
tologic subtype, and ¢nd the frequency of mutation to be less
frequent than initial reports of B-raf mutation (2003). B-raf is a
member of the raf family of oncogenes, which includes A, B, and
C-raf. These closely related genes stand in a pivotal section of the
Ras-Map kinase pathway, in which raf proteins bind to mem-
brane localized ras oncogenes and transmit signals to MAP kinase
kinase (MEKK), which then transmits signals to MAP kinase
(ERK, p42/44), which has a variety of downstream e¡ects, in-
cluding activation of AP-1, resulting in protumorigenic and
proangiogenic e¡ects, such as stimulation of vascular endothelial
growth factor (VEGF), matrix metalloproteinases (MMPs), and
tissue factor (TF) (Cohen et al, 2002; Govindarajan et al, 2003).
After B-raf mutations were discovered to be the most prevalent
mutations in human melanoma, they were described as occurring
in high frequency in atypical nevi as well (Davies et al, 2002; Pol-
lock et al, 2003). This data shows that while B-raf mutations play
an important role in human melanoma, they are by themselves
neither necessary nor su⁄cient for the development of human
melanoma. The data of Yazdi et al are consistent with these
¢ndings.
How do B-raf mutations ¢t into the current understanding of
the multistep progression of melanomagenesis? Two genetic mu-
tations are associated with atypical nevi, which are generally ac-
cepted to be precursors of melanoma. Many melanomas arise
from atypical nevi, which have two genetic mutations associated
with them. Hemizygosity of p16ink4a and activating mutations
of B-raf have each been found in a proportion of nevi, and the
data of Yazdi et al suggest that B-raf mutations have been found
in a particular subset of nevi (Haluska and Hodi, 1998;
Sviderskaya et al, 2002). This is analogous to the ¢nding of ampli-
¢cation of H-ras in a histologic subset of Spitz nevi (Bastian et al,
2000).
Normal cells, including melanocytes, have defenses against
oncogenic activation. Expression of mutant B-raf in normal mel-
anocytes causes induction of a defensive enzyme, MAP kinase
phosphatase, which as the name implies, results in dephosphory-
lation and inactivation of MAP kinase (Connor et al, 2003).We
have previously shown that activated MAP kinase is present in
radial growth melanoma, but not atypical nevi, and that intro-
duction of active MAP kinase kinase (MEKK) is su⁄cient to
convert immortalized melanocytes into radial growth-like mela-
noma in mice.The ¢nding of B-raf mutations, which can activate
MAP kinase signaling in atypical nevi, suggests that loss of MAP
kinase phosphatase is necessary to convert atypical nevi into mel-
anoma, and allows us to predict that MAP kinase phosphatase is a
tumor suppressor gene that is lost early in melanomagenesis. Ef-
forts are currently underway in our laboratory to determine
whether this is the case. A proposed pathway of melanoma pro-
gression is illustrated in Fig 1.
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Figure 1. Proposed role of MAP kinase phosphatase as a mela-
noma tumor suppressor.
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